Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07411261
Starting soon Not applicable

PremaBiom: Metatranscriptomics of the Respiratory Microbiome to Predict the Occurrence of Bronchopulmonary Dysplasia in Preterm Infants

NCT07411261 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-03
Last updated
2026-02-13

Condition(s) studied

Bronchopulmonary DysplasiaPreterm Infant DevelopmentAsthma ChildhoodBronchiolitisViral Respiratory Tract Infections

Investigational drug(s) / intervention(s)

Nasal swabblood sampling →Mother milk samplingStool sampling →

Nasal swab: Nasal swab is performed by nurses at birth (within 72 hours), and each week during initial neonatal care unit stay. After discharge, nasal swabs will be performed by parents at home and sent by post to the investigational center.

blood sampling: For 50-60 patients: 1 mL of blood sampling will be performed once during current care blood test (without additional blood draw), around 36 gestational weeks (+/- 1 week).

Mother milk sampling: For 50-60 patients: 1 mL of mother milk will be sampled once during hospital stay in case of breastfeeding.

Stool sampling: Stool sampling will occure at birth (within 72 hours after birth), then once a week during neonatal unit stay.

Study summary

The goal of this clinical trial is to understand the impact of respiratory microbiome maturation in respiratory health of preterm infants under 32 gestational weeks. The main questions it aims to answer are:

* What is the role of microbiome maturation in respiratory health (development of bronchopulmonary dysplasia, childhood asthma and viral respiratory infections) of preterm infants ?
* Which environmental or health factors are involved in the maturation of the respiratory microbiome ?

Participants will undergo follow-up from birth until 3 years of corrected age including nasal swabs, stool samples, and for some of them blood and milk sample.

Eligibility

Sex
ALL
Min age
—
Max age
72 Hours
Healthy volunteers
No
Inclusion Criteria: * Preterm infants with gestational age at birth lower than 32 gestational weeks and 6 days. * Hospital stay in one of the participant neonatal care units * Infants covered by the social security system of at least one of their parents * Whose parents have been informed about the study and agree to sign the informed consent form Exclusion Criteria: * Palliative care only * Lack of parental consent * Parents who are minors or under legal protection (guardianship, conservatorship, judicial protection) * Parents who do not speak French

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Service de néonatalogie, CHU d'Amiens Amiens France
Service de néonatalogie, CHU de Caen Caen France
Service de néonatalogie, CH Cherbourg-en-Cotentin Cherbourg France
Service de néonatalogie, GHT du Havre Le Havre France
Service de néonatalogie, CHRU de Lille Lille France
Service de néonatalogie, CHU de Rouen Rouen France

More University Hospital, Caen trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07411261 on ClinicalTrials.gov ↗ ← All trials in France